A new neuroimaging marker of cerebral small vessel disease is related to general cognition and may serve to identify persons at risk of dementia in future clinical trials, a landmark study has found.
Which Food Allergy Patients Will Benefit Most From Omalizumab?
Data presented at the recent American Academy of Allergy, Asthma & Immunology annual meeting showed that routine injections of omalizumab (Xolair) slashed the severity of
April 9, 2024